Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats

about

Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats

Item

http://www.wikidata.org/entity/Q40957849

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Docetaxel Accumulates in Lymph ...... o Intravenous Delivery in Rats

@en

type

Item

label

Docetaxel Accumulates in Lymph ...... o Intravenous Delivery in Rats

@en

prefLabel

Docetaxel Accumulates in Lymph ...... o Intravenous Delivery in Rats

@en

P1476

Docetaxel Accumulates in Lymph ...... o Intravenous Delivery in Rats

@en

P2093

Daniel L Gustafson

http://www.w3.org/2001/XMLSchema#string

Deanna R Worley

http://www.w3.org/2001/XMLSchema#string

Laura S Chubb

http://www.w3.org/2001/XMLSchema#string

Luke A Wittenburg

http://www.w3.org/2001/XMLSchema#string

Ryan J Hansen

http://www.w3.org/2001/XMLSchema#string

P2860

Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer

Taxanes: vesicants, irritants, or just irritating?

Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.

Lymphangiogenesis and lymphatic metastasis in breast cancer.

Liposomes to target the lymphatics by subcutaneous administration.

Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents.

Lymphatic biology and the microcirculation: past, present and future.

Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.

Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas

A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo.

P304

5071-5078

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21873/ANTICANRES.11076

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27798866

http://www.w3.org/2001/XMLSchema#string

P932

5501171

http://www.w3.org/2001/XMLSchema#string